Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

10.80 EUR+8.22 %4.9, 17.29
5,685 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
+8.22 %
+15.14 %
+20.81 %
+19.21 %
-23.94 %
-17.56 %
+261.20 %
+120.41 %
-98.22 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
87.21M EUR
Turnover
147.4K EUR
P/E (adj.) (26e)
131.97
EV/EBIT (adj.) (26e)
65.68
P/B (26e)
8.83
EV/S (26e)
6.15
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
16.08.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
3rd party
ShowingAll content types

Forum discussions
Sixth for a new university hospital in Europe: nexstim.com Nexstim - Releases
yesterday
by ghoul
39
The unsuccessful Aiforia was removed from the model portfolio. Nexstim would offer a good playing field for the model portfolio. The stock has dropped nicely from its peaks and plateaued at its current levels. Profitability has been reached and this year will be a record year. Own...
yesterday
by Umpi
31
Inderes predicted 52 systems for the whole year. Now we are 12 systems away from that, and the last quarter hasn’t even started yet. And now we are facing the first Q4 where the Brainlab partnership has been active throughout the entire sales pipeline. The rolling 12-month delivery...
yesterday
by Matti Kukkaro
26
Through Brainlab, sales are certainly weighted toward the end of the year, as the seasonal fluctuation is driven precisely by customers and their decision-making rather than sales resources. In addition to Brainlab, therapy and research equipment are also being sold. In the final...
22 hours ago
by Kyhnykeisari
24
The momentum is really great, I can’t remember even around Christmas time previously having trades four days in a row.
yesterday
by ghoul
20
September has gotten off to a pretty nice start in terms of trades
yesterday
by Apesor
12
For the past year or two, it has been said that Brainlab’s impact on sales will become prominent for the first time in late 2026… properly. Therefore, given that there has been a considerable number of commenters/experts, I find it hard to believe the scenario you mentioned. Rather...
23 hours ago
by Taitoo
9
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release04.09.2026, 08.00

European University Hospital Orders Nexstim NBS 6 System

Nexstim
Press release03.09.2026, 08.00

Nordic Private Clinic Expands Use with Additional NBS 6 System

Nexstim
Third party research02.09.2026, 08.11

Nexstim: Stimulating growth with surgical accuracy; INITIATE with BUY - NuWays AG Research

Nexstim is a Finnish MedTech company and a global leader in navigated transcranial magneticstimulation (nTMS) technology. With nTMS, Nexstim helps (i) surgeons preserve patients' motor and speech cortices and (ii) clinicians treat neurological and psychiatric...

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release02.09.2026, 08.00

US University Customer Purchases Nexstim NBS 6 for Research Purposes

Nexstim
Press release01.09.2026, 08.00

European Hospital Orders Nexstim NBS 6 System

Nexstim
Press release21.08.2026, 08.00

Nexstim Receives NBS 6 System Order for a European hospital and existing Nexstim customer

Nexstim
Regulatory press release20.08.2026, 12.00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Press release19.08.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from New US Customer

Nexstim
Nexstim H1'26: Brainlab potential to be weighed later this year
Research17.08.2026, 09.09 by
Antti Siltanen

Nexstim H1'26: Brainlab potential to be weighed later this year

Concrete evidence of the Brainlab collaboration's potential will be available during the rest of the year.

Nexstim
Regulatory press release14.08.2026, 08.00

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2026 (UNAUDITED)

Nexstim
Press release11.08.2026, 08.00

Notice of Nexstim Plc’s Half-Year Report H1 2026

Nexstim
Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate
Analyst Comment11.08.2026, 08.25 by
Antti Siltanen

Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate

We expect the dip in recurring revenue to have weighed on earnings.

Nexstim
Press release31.07.2026, 12.00

Finnish Private Clinic Group Orders Additional Nexstim NBS 6 System

Nexstim
Regulatory press release20.07.2026, 12.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Press release17.07.2026, 08.00

Delve Psychiatry Upgrades to Nexstim's Latest NBS 6 Platform

Nexstim
Press release15.07.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from a Neurology Clinic in the United States

Nexstim
Nexstim received another order for ten NBS 6 systems
Analyst Comment15.07.2026, 08.01 by
Frans-Mikael Rostedt

Nexstim received another order for ten NBS 6 systems

The second order for ten systems within a month indicates the rapid scaling of the distribution partnership.

Nexstim
Press release14.07.2026, 08.00

Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor

Nexstim
Press release10.07.2026, 08.00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release08.07.2026, 08.00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim